#None #Chicago #ZIIHERA #Jazz Pharmaceuticals #Zepzelca

Jazz Pharmaceuticals Presents Cutting-Edge Oncology Data at ASCO 2026

Jazz Pharmaceuticals, a global biopharma company dedicated to transforming the lives of patients, is gearing up for a significant presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 to June 2, 2026, in Chicago. The company, listed on Nasdaq as JAZZ, has announced it will share findings through three rapid oral and seven poster presentations highlighting advancements in oncology, particularly focusing on two of its key products: Ziihera® (zanidatamab-hrii) and Zepzelca® (lurbinectedin).

Key Highlights of the ASCO Presentations

At ASCO 2026, Jazz will present important results from their Phase 3 trials. The findings will delve into how Ziihera and Zepzelca are elevating treatment standards for patients facing tough battles against gastroesophageal adenocarcinoma (GEA) and extensive-stage small cell lung cancer (ES-SCLC).

Ziihera (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma

One of the focal points of Jazz's presentations will be data from the Phase 3 HERIZON-GEA-01 trial, which explored Ziihera in conjunction with chemotherapy, evaluating the drug’s efficacy in previously untreated patients suffering from HER2-positive GEA. This trial also investigated the impact of adding the PD-1 inhibitor Tevimbra® (tislelizumab) to enhance patient outcomes. Key analyses include:

• - Progression-Free Survival (PFS) and Overall Survival (OS) across various PD-L1 subgroups.
• - Characterization and management of gastrointestinal adverse events linked to the treatment.

Dr. Rob Iannone, the Global Head of Research and Development at Jazz Pharmaceuticals, emphasized that the additional analyses presented at ASCO will continue to aid in treatment decision-making, providing invaluable data to integrate Ziihera into clinical practice successfully.

Zepzelca (lurbinectedin) for Small Cell Lung Cancer

In addition to Ziihera, Jazz will reveal findings from the Phase 3 IMforte trial, which studies the combination of Zepzelca with atezolizumab (Tecentriq®) as a first-line maintenance treatment for patients with ES-SCLC. Presentations will discuss:

• - Quality-adjusted time without symptoms or toxicity.
• - Quick impacts across various SCLC molecular subtypes.

Expert Insights

Iannone commented on the importance of these data, underlining Jazz’s commitment to innovating treatment options for patients grappling with one of the most difficult-to-treat cancers. He stated, "These findings exemplify our dedication to building an increasingly differentiated oncology portfolio, thereby contributing advancements in the treatment arena."

Conclusion

With an array of pivotal studies slated for ASCO 2026, Jazz Pharmaceuticals is poised to demonstrate its commitment to empowering clinicians in delivering transformative therapies to patients. As it shares this crucial data, Jazz reaffirms its role as a key player in the oncology landscape, continually striving to enhance therapeutic options for patients who need them most. For more detailed abstracts, interested parties can visit the ASCO website to view the full list of presentations.

This year’s ASCO meeting is anticipated to be a crucial platform for Jazz Pharmaceuticals, where new research and evidence will pave the way for refined treatment protocols in oncology, further establishing Jazz’s legacy in the biopharmaceutical field.